Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, November 5, 2026

Back to the front page

From X

@convequity

Convequity on X

$TSEM remains one of our highest-conviction holdings, even after we trimmed the position in our 4Q26 rebalance. We wanted to keep Tower at its 6.1% portfolio weight despite a roughly 25% fall in its share price over the past quarter. To make room for new holdings, we trimmed the weight to 4.75% and banked some profits. With SpaceX ($SPCX) also becoming a larger holding, we are limiting further additions to avoid concentrating the portfolio in a few companies. Our confidence in Tower's technology remains strong. We think Tower's competitive advantage comes from combining chips that send and receive data using light with the electronic chips that drive and control them. Next-generation optical connections require these components to exchange more data within a smaller space. Hybrid bonding achieves this by joining the chips through densely packed electrical connections that move large amounts of data in a compact package. In our view, Tower's capabilities here are effectively unmatched among Western suppliers. Tower has also added manufacturing capacity more successfully than we expected. It can fulfill more customer orders itself, leaving less business for $GFS. Customers have less reason to switch to a supplier whose technology they consider weaker when Tower can meet their needs, so the capacity expansion strengthens our Tower thesis and weakens the case for competitors that rely on orders Tower cannot accommodate.

Investor Letters

All letters

Trading Post November 5, 2026

MercadoLibre’s logistics expansion cut margins by 60 basis points, while Mercado Pago grew credit 62% with 7% NPLs.

MELI $77B
Cassandra Unchained 2 clicks

Intel: The CPU Comeback, Discounted

Intel's Q3 2026 results were hit by memory costs and an Israel shutdown, but enterprise AI inference could lift CPU demand as server…

INTC $287B
Monte Independent Investment Research 2 clicks

Problems at Twist Bioscience (TWST)

Twist Bioscience’s $200 rebound followed an Anthropic-linked short squeeze, yet its DNA and protein services face broad competition while…

TWST $8B
Hunterbrook 4 clicks

VSH Earnings Review

Vishay reported record Q3 revenue of $979 million, up 24%, and guided Q4 to about $990 million as rising backlog and margins contrast with…

VSH $3.6B
Cestrian Capital Research 3 clicks

Thursday Tailwinds #13: Nov 5, 2026

Florida marinas are 92% full as boat counts rise and permits constrain new supply, creating pricing power for existing operators such as…

SUI $14B
Trade Ideas Flow 6 clicks
CHWY · long

Chewy INC

Chewy (CHWY) is presented as a long opportunity after a prior 2022 short thesis played out.

CHWY $9.2B
Value Investors Club 5 clicks

New Ideas From The Road

Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…

AA $10BNKE $60B
Aurelion Research 4 clicks

Site Centers (NYSE:SITC)

Site Centers' $3 per-share return-of-capital distribution and December delisting leave a discounted liquidation stub, with two properties…

CURB $3.6B
Real Assets, Real Value 5 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 278

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.